Qiu Chunfang, Luthy David A, Zhang Cuilin, Walsh Scott W, Leisenring Wendy M, Williams Michelle A
Center for Perinatal Studies, Swedish Medical Center, 747 Broadway, Suite 449 North, Seattle, WA 98122, USA.
Am J Hypertens. 2004 Feb;17(2):154-60. doi: 10.1016/j.amjhyper.2003.09.011.
We measured C-reactive protein (CRP), a clinical marker of systemic inflammation, in maternal serum collected at 13 weeks gestation on average, to determine whether elevations precede the clinical manifestation of preeclampsia.
Using a prospective, nested, case-control study design we measured CRP concentrations using a competitive immunoassay in 60 women who developed preeclampsia and in 506 women who remained normotensive throughout pregnancy. Logistic regression procedures were used to calculate odds ratio (OR) and 95% CI. Because maternal serum CRP is highly correlated with maternal prepregnancy body mass index (BMI), all analyses were repeated after stratification by maternal prepregnancy overweight status (BMI <25 v > or =25 kg/m(2)).
Overall, the risk of preeclampsia increased across successively higher tertiles of CRP (OR = 1.0, 1.6, and 3.5, with the lowest tertile as the referent group; P <.001 for trend). After adjusting for parity and first-degree family history of chronic hypertension, the OR in the highest tertile was 3.2 (95% CI = 1.5 to 6.7). Further adjustment for BMI greatly attenuated this association (OR = 1.8, 95% CI = 0.8 to 4.1). Elevated CRP concentrations (> or =4.9 mg/L) were associated with a 2.5-fold increased risk of preeclampsia (95% CI = 1.1 to 5.5) in lean women. No similar association was observed among overweight women.
Elevated CRP is highly correlated with prepregnancy adiposity and appears to be an independent predictor of preeclampsia in lean women. Further work is needed to identify modifiable risk factors for systemic inflammation in early pregnancy and to explore further the extent to which CRP and prepregnancy adiposity independently and jointly contribute to preeclampsia risk.
我们检测了平均在妊娠13周时采集的母血中C反应蛋白(CRP),这是一种全身性炎症的临床标志物,以确定其升高是否早于子痫前期的临床表现。
采用前瞻性巢式病例对照研究设计,我们用竞争性免疫测定法检测了60例发生子痫前期的妇女和506例整个孕期血压正常的妇女的CRP浓度。采用逻辑回归程序计算比值比(OR)和95%可信区间(CI)。由于母血CRP与孕前体重指数(BMI)高度相关,所有分析在按孕前超重状态(BMI<25对≥25kg/m²)分层后重复进行。
总体而言,子痫前期的风险随着CRP三分位数的升高而增加(OR分别为1.0、1.6和3.5,以最低三分位数作为参照组;趋势P<.001)。在调整了产次和慢性高血压一级家族史后,最高三分位数的OR为3.2(95%CI=1.5至6.7)。进一步调整BMI后,这种关联大大减弱(OR=1.8,95%CI=0.8至4.1)。CRP浓度升高(≥4.9mg/L)与瘦女性子痫前期风险增加2.5倍相关(95%CI=1.1至5.5)。超重女性中未观察到类似关联。
CRP升高与孕前肥胖高度相关,似乎是瘦女性子痫前期的独立预测因素。需要进一步开展工作,以确定孕早期全身性炎症的可改变风险因素,并进一步探讨CRP和孕前肥胖在子痫前期风险中独立和共同作用的程度。